Form 10-K Amendment No. 1

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-K/A

(Amendment No. 1)

 

 

(Mark one)

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2008

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 000-30347

 

 

CURIS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

DELAWARE   04-3505116

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

45 Moulton Street

Cambridge, Massachusetts 02138

(Address of principal executive offices) (Zip Code)

617-503-6500

(Registrant’s telephone number, including area code)

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Name of Each Exchange on Which Registered

Common Stock, $0.01 par value per share   The NASDAQ Stock Market

Securities registered pursuant to Section 12(g) of the Act:

None

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ¨    No  x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ¨    No  x

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.    ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ¨    Accelerated filer   x
Non-accelerated filer   ¨  (Do not check if a smaller reporting company)    Smaller reporting company   x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ¨    No  x

The aggregate market value of the registrant’s common stock held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate) based on the last reported sale price of the common stock on June 30, 2008 was approximately $62,390,000.

As of February 24, 2009, there were 63,653,698 shares of the registrant’s common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

The registrant has filed a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2008. Portions of such proxy statement are incorporated by reference into Items 10, 11, 12, 13, 14 of Part III of the Annual Report on Form 10-K, as amended.

 

 

 


EXPLANATORY NOTE

Curis, Inc. is filing this Amendment No. 1 (“Amendment No. 1”) to its Annual Report on Form 10-K for the fiscal year ended December 31, 2008, as originally filed with the SEC on February 26, 2009 (the “Original 10-K”), for the purpose of: (1) amending Part III Item 12 thereof to include disclosure regarding securities authorized for issuance under equity compensation plans; and (2) amending and restating Part III Item 15(a)(3) “List of Exhibits” to add new certifications in accordance with Rule 13a-14(a) of the Exchange Act, which are filed as exhibits with this 10-K/A.

This Amendment No. 1 does not change the previously reported financial statements or any of the other disclosure contained in the Original 10-K.

PART III

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Securities Authorized for Issuance Under Equity Compensation Plans

The following table provides information as of December 31, 2008 regarding compensation plans (including individual compensation arrangements) under which our equity securities are authorized for issuance.

 

    

(a)

  

(b)

  

(c)

     Number of
securities to
be issued upon
exercise

of outstanding
options,
warrants and
rights
   Weighted-
average
exercise price of
outstanding
options,
warrants and
rights
   Number of
securities
remaining
available for
future issuance
under equity
compensation
plans (excluding
securities reflected
in column (a))

Equity compensation plans approved by security holders

   10,450,759    $ 2.67    4,376,856

Equity compensation plans not approved by security holders

   —        —      —  
                

Total

   10,450,759    $ 2.67    4,376,856
                

Beginning on January 1, 2001 and continuing through January 1, 2010, the number of shares of common stock reserved for issuance under the 2000 Stock Incentive Plan is automatically increased by the lesser of 1,000,000 shares or 4% of outstanding stock on January 1 of each year.


The other information required by this Item 12 is set forth in our proxy statement for our 2009 annual meeting of stockholders under the heading Security Ownership of Certain Beneficial Owners and Management, which information is incorporated herein by reference.

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a)(3) List of Exhibits. The list of Exhibits filed as a part of this annual report on Form 10-K as amended by this Amendment No. 1 is set forth on the Exhibit Index immediately preceding such Exhibits, and is incorporated herein by reference.


SIGNATURE

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

CURIS, INC.
    /S/    DANIEL R. PASSERI        
Name:   Daniel R. Passeri
Title:   President and Chief Executive Officer

Date: November 13, 2009


EXHIBIT INDEX

 

          

Incorporated by Reference

Exhibit

No.

  

Description

  

Form

  

SEC Filing

Date

  

Exhibit
Number

  

Filed with
this 10-K

   Articles of Incorporation and By-laws            

    3.1

   Restated Certificate of Incorporation of Curis, Inc.    S-4/A (333-32446)    06/19/00    3.3   

    3.2

   Certificate of Designations of Curis, Inc.    S-3 (333-50906)    08/10/01    3.2   

    3.3

   Amended and Restated By-laws of Curis, Inc.    S-1 (333-50906)    11/29/00    3.2   

    3.4

   Amendment to Amended and Restated By-laws of Curis, Inc.    8-K    09/24/07    3.1   
   Instruments defining the rights of security holders, including indentures            

    4.1

   Form of Curis Common Stock Certificate    10-K    03/01/04    4.1   
   Material contracts—Management Contracts and Compensatory Plans            

#10.1

   Employment Agreement, dated as of September 18, 2007, between Curis and Daniel R. Passeri    8-K    09/24/07    10.1   

#10.2

   Amendment to Employment Agreement, dated as of October 31, 2006, to the employment agreement dated September 20, 2001, by and between Curis and Daniel R. Passeri    8-K    11/02/06    10.2   

#10.3

   Amendment to Employment Agreement, dated as of October 27, 2008, to the employment agreement dated September 18, 2007, by and between Curis and Daniel R. Passeri    10-Q    10/28/08    10.1   

#10.4

   Offer Letter, dated as December 10, 2003, between Curis and Michael P. Gray    10-K    03/01/04    10.4   

#10.5

   Amendment to Offer Letter, dated as of October 31, 2006, to the offer letter dated December 10, 2003, by and between Curis and Michael P. Gray    8-K    11/02/06    10.3   

#10.6

   Amendment to Offer Letter, dated as of October 27, 2008, to the offer letter dated December 10, 2003, by and between Curis and Michael P. Gray    10-Q    10/28/08    10.2   

#10.7

   Offer Letter, dated May 2, 2001, by and between Curis and Changgeng Qian    10-K    3/14/08    10.5   

#10.8

   Amendment to Offer Letter, dated as of May 10, 2002, to the offer letter dated May 2, 2001, by and between Curis and Changgeng Qian    10-K    3/14/08    10.6   

#10.9

   Amendment to Offer Letter, dated as of December 14, 2006, to the offer letter dated May 2, 2001, as amended on May 10, 2002, by and between Curis and Changgeng Qian    10-K    3/14/08    10.7   

#10.10

   Amendment to Offer Letter, dated as of October 27, 2008, to the offer letter dated May 2, 2001, by and between Curis and Changgeng Qian    10-Q    10/28/08    10.3   

#10.11

   Offer Letter, dated January 11, 2001, by and between Curis and Mark W. Noel    10-K    03/02/07    10.6   

#10.12

   Amendment to Offer Letter, dated as of October 31, 2006, to the offer letter dated January 11, 2001, by and between Curis and Mark W. Noel    8-K    11/02/06    10.4   

#10.13

   Amendment to Offer Letter, dated as of October 27, 2008, to the offer letter dated January 11, 2001, by and between Curis and Mark W. Noel    10-Q    10/28/08    10.4   

#10.14

   Offer Letter, dated as of July 25, 2002, between Curis and Mary Elizabeth Potthoff    10-K    03/01/04    10.5   

#10.15

   Amendment to Offer Letter, dated as of October 31, 2006, to the offer letter dated July 25, 2002, by and between Curis and Mary Elizabeth Potthoff    8-K    11/02/06    10.5   

#10.16

   Agreement and General Release, dated as of June 25, 2007, by and between Curis and Mary Elizabeth Potthoff    10-Q    07/31/07    10.1   

#10.17

   Consulting Agreement dated June 19, 2006 by and between Curis and Joseph M. Davie, Ph. D., M.D.    8-K    08/29/06    10.1   

#10.18

   First Amendment to Consulting Agreement, dated as of October 30, 2006, between Curis and Joseph M. Davie, Ph.D., M.D.    8-K    11/02/06    10.1   

#10.19

   Scientific Advisory Agreement dated September 14, 2006 by and between Curis and Joseph M. Davie, Ph. D., M.D.    8-K    09/19/06    10.2   

#10.20

   Agreement for Service as Chairman of the Board of Directors, between Curis, Inc. and James McNab, dated as of June 1, 2005    8-K    06/07/05    10.1   


#10.21

   Form of Indemnification Agreement, between Curis, Inc. and each member of the Board of Directors named on Schedule I thereto    10-Q    08/09/05    10.5   

#10.22

   Indemnification Agreement between Curis, Inc. and Dr. Stephen Carter, dated January 29, 2008    8-K    1/31/08    10.1   

#10.23

   Consulting Agreement dated May 11, 2007 by and between Curis and Dr. Stephen Carter.    10-K    3/14/08    10.19   

#10.24

   Curis 2000 Stock Incentive Plan    S-4/A (333-32446)    05/31/00    10.71   

#10.25

   Curis 2000 Director Stock Option Plan    S-4/A (333-32446)    05/31/00    10.72   

#10.26

   Curis 2000 Employee Stock Purchase Plan    S-4/A (333-32446)    05/31/00    10.73   

#10.27

   Form of Incentive Stock Option Agreement granted to directors and named executive officers under Curis’ 2000 Stock Incentive Plan    10-Q    10/26/04    10.2   

#10.28

   Form of Non-statutory Stock Option Agreement granted to directors and named executive officers under Curis’ 2000 Stock Incentive Plan    10-Q    10/26/04    10.3   

#10.29

   Form of Non-statutory Stock Option Agreement granted to non-employee directors under Curis’ 2000 Director Stock Option Plan    10-Q    10/26/04    10.4   
   Material contracts—Leases            

  10.30

   Lease, dated November 16, 1995, as amended, between Ontogeny, Inc., Moulton Realty Corporation and the trustees of Moulton Realty Trust relating to the premises at 33 and 45 Moulton Street, Cambridge, Massachusetts    S-4 (333-32446)    03/14/00    10.42   

  10.31

   Lease, dated March 15, 2001, between Curis and Moulton Realty Company relating to the premises at 61 Moulton Street, Cambridge, Massachusetts    10-K    03/30/01    10.3   

  10.32

   Amendment to Lease, dated August 9, 2002, between Curis and FPRP Moulton LLC relating to the premises at 25, 27, 33, 45 and 61 Moulton Street, Cambridge, Massachusetts    10-Q    11/12/02    10.1   

  10.33

   Second Amendment to Leases, dated August 17, 2004, between Curis and FPRP Moulton LLC relating to the premises at 25, 27, 33, 45 and 61 Moulton Street, Cambridge, Massachusetts    10-Q    10/26/04    10.1   
   Material contracts—Financing Agreements            

  10.34

   Line of Credit Agreement for the Acquisition of Equipment and Leasehold Improvements, restated on September 23, 2004, between Curis and Boston Private Bank & Trust Company    10-K    03/15/05    10.18   

  10.35

   Security Agreement, dated restated on September 23, 2004, between Curis and Boston Private Bank & Trust Company    10-K    03/15/05    10.19   

  10.36

   Secured Non-Revolving Time Note, dated restated on September 23, 2004, made by Curis in favor of Boston Private Bank & Trust Company    10-K    03/15/05    10.20   

  10.37

   Line of Credit Agreement for the Acquisition of Equipment and Leasehold Improvements, between Curis, Inc. and Boston Private Bank & Trust Company, dated as of June 9, 2005    8-K    06/15/05    10.1   

  10.38

   Secured Non-Revolving Time Note, issued by Curis, Inc. to Boston Private Bank & Trust Company, dated June 9, 2005    8-K    06/15/05    10.2   

  10.39

   Security Agreement (Equipment), between Curis, Inc. and Boston Private Bank & Trust Company, dated June 9, 2005    8-K    06/15/05    10.3   
   Material contracts—License and Collaboration Agreements            

†10.40

   License Agreement, dated as of February 12, 1996, between Curis and Leland Stanford Junior University    S-4/A (333-32446)    06/02/00    10.43   

†10.41

   License Agreement, dated as of January 1, 1995 as amended on July 19, 1995 and August 30, 1996, between Ontogeny and The Trustees of Columbia University in the City of New York    S-4/A (333-32446)    04/03/00    10.45   

†10.42

   Amended and Restated License Agreement, dated June 1, 2003, between Curis, The Johns Hopkins University and University of Washington School of Medicine    10-K    03/01/04    10.23   

†10.43

   Amended and Restated License Agreement (2000), dated June 10, 2003, between Curis and the President and Fellows of Harvard University    10-K    03/01/04    10.24   


†10.44

   Amended and Restated License Agreement (1995), dated June 10, 2003, between Curis and the President and Fellows of Harvard University    10-K    03/01/04    10.25   

†10.45

   Agreement, dated as of November 27, 2002, by and between Curis and Ortho Biotech Products, L.P.    8-K    12/09/02    10.1   

†10.46

   Collaborative Research, Development and License Agreement, dated June 11, 2003, between Curis and Genentech, Inc.    8-K    07/10/03    10.1   

  10.47

   First Amendment to Collaborative Research, Development and License Agreement, effective December 10, 2004, between Curis and Genentech, Inc.    10-K    03/15/05    10.33   

  10.48

   Second Amendment to Collaborative Research, Development and License Agreement between Curis and Genentech effective as of April 11, 2005    8-K    04/19/05    99.1   

†10.49

   Drug Discovery and Collaboration Agreement dated April 1, 2005 by and between Curis, Inc. and Genentech, Inc.    10-Q    4/29/05    10.1   

†10.50

   Collaboration, Research and License Agreement, dated January 12, 2004, between Curis and Wyeth    10-K    03/01/04    10.29   

†10.51

   Collaboration, Research and License Agreement dated September 18, 2005 by and between Curis, Inc. and Procter & Gamble Company    10-Q    11/14/05    10.1   
   Material contracts—Miscellaneous            

  10.52

   Termination Agreement and Amendments to Finance Documents, dated May 16, 2003, between Elan Corporation, PLC, Neuralab Limited, Elan International Services, LTD, Elan Pharma International Limited, Curis, Inc. and Curis Newco, LTD    8-K    06/03/03    10.1   

  10.53

   Registration Rights Agreement, dated June 13, 2003, between Curis and Genentech, Inc.    8-K    07/10/03    10.3   

  10.54

   Common Stock Purchase Agreement, dated June 11, 2003, between Curis and Genentech, Inc.    8-K    07/10/03    10.2   

  10.55

   Common Stock Purchase and Registration Rights Agreement, dated January 9, 2004, between Curis and Wyeth    10-K    03/01/04    10.34   

  10.56

   Form of Common Stock and Warrant Purchase Agreement, dated August 11, 2003, entered into by Curis and certain investors, together with a schedule of such investors and the material details of each such agreement    10-Q    11/12/03    10.1   

  10.57

   Form of Stock Purchase Agreement, dated as of October 12, 2004, entered into by Curis and each of the purchasers, together with a schedule of purchasers who are parties thereto    8-K    10/14/04    10.1   

  10.58

   Common Stock Purchase Agreement, dated as of August 6, 2007, by and among the Company and the Purchasers (as defined therein), as amended by Amendment to Common Stock Purchase Agreement and Waiver, dated August 7, 2007    8-K    08/09/07    10.1   

  10.59

   Common Stock Purchase Agreement, dated as of August 7, 2007, by and among the Company and the Purchasers (as defined therein)    8-K    08/09/07    10.2   

  10.60

   Registration Rights Agreement, dated as of August 6, 2007, by and among the Company and the Purchasers (as defined therein), as amended by Amendment to Registration Rights Agreement, dated August 7, 2007    8-K    08/09/07    10.3   

  10.61

   Form of Warrant, dated August 8, 2007, issued pursuant to the Common Stock Purchase Agreement, dated as of August 6, 2007, as amended on August 7, 2007    8-K    08/09/07    10.4   

  10.62

   Form of Warrant, dated August 8, 2007, issued pursuant to the Common Stock Purchase Agreement, dated as of August 7, 2007    8-K    08/09/07    10.5   
   Code of Conduct            

  14

   Code of Business Conduct and Ethics    10-K    03/01/04    14   
   Additional Exhibits            

  21

   Subsidiaries of Curis    10-K    02/26/09      

  23.1

   Consent of PricewaterhouseCoopers LLP    10-K    02/26/09      


  31.1

   Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act/15d-14(a) of the Exchange Act    10-K    02/26/09      

  31.2

   Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act/15d-14(a) of the Exchange Act    10-K    02/26/09      

  32.1

   Certification of the Chief Executive Officer pursuant to Rule 13a-14(b)/15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350    10-K    02/26/09      

  32.2

   Certification of the Chief Financial Officer pursuant to Rule 13a-14(b)/15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350    10-K    02/26/09      

  32.3

   Certification of the Chief Executive Officer pursuant to Rule 13a-14(b)/15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350             X

  32.4

   Certification of the Chief Financial Officer pursuant to Rule 13a-14(b)/15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350             X

 

# Indicates management contract or compensatory plan or arrangement.
Confidential treatment has been requested as to certain portions, which portions have been separately filed with the Securities and Exchange Commission.